Segment disclosures

Company overview

명인제약

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 13 retained observations 9 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Consolidated

Consolidated And Separate Financial Statements

Source dimensions ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis=ifrs-full:ConsolidatedMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3076106145635 KRW20260813Open filing evidence
2026-01-01 – 2026-06-30148241945597 KRW20260813Open filing evidence
2026-01-01 – 2026-03-3172135799962 KRW20260514Open filing evidence
2025-01-01 – 2025-12-31287254358952 KRW20260325Open filing evidence
2025-07-01 – 2025-09-3072697477352 KRW20251112Open filing evidence
2025-01-01 – 2025-09-30215162686788 KRW20251112Open filing evidence
2025-04-01 – 2025-06-3072210220783 KRW20260813Open filing evidence
2025-01-01 – 2025-06-30142465209436 KRW20260813Open filing evidence
2025-01-01 – 2025-03-3170254988653 KRW20260514Open filing evidence
2024-01-01 – 2024-12-31269434788789 KRW20260325Open filing evidence
2024-07-01 – 2024-09-3070007878798 KRW20251112Open filing evidence
2024-01-01 – 2024-09-30201290233492 KRW20251112Open filing evidence
2023-01-01 – 2023-12-31242337808007 KRW20260325Open filing evidence